Welcome to our dedicated page for APOLLOMICS SEC filings (Ticker: APLMW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial data, dilution clauses, and warrant conversions make Apollomics filings daunting. If you have ever searched for the single paragraph that explains a vebreltinib milestone payment or an uproleselan safety update, you know the challenge.
Stock Titan solves this problem. Our AI reads every Apollomics SEC document the minute it lands on EDGAR, turns the legalese into clear language, and flags what matters—cash runway in the quarterly earnings report 10-Q filing, pipeline risks hidden in the annual report 10-K simplified, or changes in leadership disclosed through 8-K material events explained.
Need Apollomics insider trading Form 4 transactions? We stream Form 4 insider transactions in real-time and highlight executive stock transactions Form 4 so you can spot buying or selling before market chatter starts. Wondering how the company funds its nine-asset oncology pipeline? The proxy statement executive compensation section and every shelf registration are linked side-by-side with AI-powered summaries that explain filing meanings in simple terms.
- Track Apollomics quarterly earnings report 10-Q filing details without paging through footnotes.
- Set alerts for "Apollomics 8-K material events" to catch trial results or financing news.
- Compare segments with our Apollomics earnings report filing analysis dashboard.
Whether you are a biotech analyst learning the science or an investor monitoring warrant dilution, understanding Apollomics SEC documents with AI gives you the clarity to make informed decisions—no more hunting through 300-page PDFs.
Apollomics Inc. disclosed on a Schedule 13D that Hung-Wen (Howard) Chen and his wholly owned vehicle, King Regent Management Limited, together hold 896,362 Class A ordinary shares, representing 41.8% of the issuer's outstanding Class A shares (2,146,151 shares outstanding as disclosed). The holdings comprise 133,334 shares directly held by Mr. Chen and 763,028 shares held by King Regent. The filing amends a prior Schedule 13G and notes that Mr. Chen is Chairman and CEO; King Regent is a private investment holding company wholly owned by him. The transaction source is identified as PIPE subscription agreements executed on September 2, 2025, and the filing includes a joint filing agreement as an exhibit.
Apollomics Inc. Schedule 13G/A filed by Maxpro Investment Co., Ltd discloses that the reporting person beneficially owns 105,071 Class A ordinary shares, representing 4.90% of the Class A shares outstanding based on 2,146,151 shares. The total includes 101,248 currently outstanding Class A shares and 3,823 Class A shares issuable upon exercise of warrants exercisable within 60 days of this filing. The filing states that on September 3, 2025 the issuer completed a private placement of 1,042,803 Class A shares, after which Maxpro ceased to be a beneficial owner of more than 5% of the Class A shares; this amendment is an exit filing reflecting that change.
Apollomics Inc. filed a Form 6-K reporting biographical details for Po-Jen Hsueh and attaching an exhibit reference to a PIPE Subscription Agreement dated September 2, 2025. The filing states Mr. Hsueh has over 15 years of experience in operations, finance, and business development in the biopharmaceutical sector, including roles as COO of ACT Genomics and prior work at TaiGen Biotechnology where he participated in multiple financing rounds that together raised $114 million USD. The registrant also notes it will furnish omitted schedules and exhibits to the SEC upon request. The report is signed by Howard Chen, Chairman, dated September 3, 2025.
FAQ
What is the current stock price of APOLLOMICS (APLMW)?
What is the market cap of APOLLOMICS (APLMW)?
